Vertex Pharmaceuticals
VRTX
VRTX
500 hedge funds and large institutions have $18.7B invested in Vertex Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 197 increasing their positions, 180 reducing their positions, and 70 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
500
Holders Change
-16
Holders Change %
-3.1%
% of All Funds
13.34%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
58
Increased
197
Reduced
180
Closed
70
Calls
$61.1M
Puts
$72.7M
Net Calls
-$11.6M
Net Calls Change
+$17M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$492M |
| 2 |
Goldman Sachs
New York
|
+$122M |
| 3 |
O
OrbiMed
New York
|
+$95.1M |
| 4 |
GE
General Electric
Evendale,
Ohio
|
+$88.3M |
| 5 |
SIG
Senator Investment Group
New York
|
+$79.5M |
Top Sellers
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$315M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$179M |
| 3 |
HCM
Hoplite Capital Management
New York
|
-$121M |
| 4 |
Jennison Associates
New York
|
-$81.8M |
| 5 |
JPMorgan Chase & Co
New York
|
-$73.9M |
